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ABSTRACT: Herein we report in vitro metabolic stability in
human liver microsomes (HLMs), interactions with cytochrome
P450 isoenzymes (CYP3A4, CYP2D6, and CYP2C9), and
cytotoxicity analyses on HEK-293, HepG2, Huh7, and WTIIB
cell lines of our most recent multitarget directed ligands PF9601N,
ASS234, and contilisant. Based on these results, we conclude that
(1) PF9601N and contilisant are metabolically stable in the HLM
assay, in contrast to the very unstable ASS234; (2) CYP3A4
activity was decreased by PF9601N at all the tested concentrations
and by ASS234 and contilisant only at the highest concentration;
CYP2D6 activity was reduced by ASS234 at 1, 10, and 25 μM and
by PF9601N at 10 and 25 μM, whereas contilisant increased its
activity at the same concentrations; CYP2C9 was inhibited by the three compounds; (3) contilisant did not affect cell viability in the
widest range of concentrations: up to 10 μM on HEK-293 cells, up to 30 μM on Huh7 cells, up to 50 μM on HepG2 cells, and up to
30 or 100 μM on WTIIB cells. Based on these results, we selected contilisant as a metabolically stable and nontoxic lead compound
for further studies in Alzheimer’s disease therapy.
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1. INTRODUCTION
Neurodegenerative diseases, such as Parkinson’s disease (PD)
and Alzheimer’s disease (AD), are characterized by a complex
pathogenesis that is the main cause of the difficulties found in
their effective treatment. An age-dependent progressive loss of
different populations of neurons, dopaminergic in PD and
cholinergic in AD, together with protein misfolding, oxidative
stress and neuroinflammation, lead to movement disturbances
in PD and cognitive impairment in AD, that are accompanied
by behavioral and psychological disorders.1−3 Currently
approved treatment strategies in PD and AD are based mainly
on enhancing the level of neurotransmitters that are lowered
due to neuronal cell death.4 These approaches temporarily
delay and reduce the symptoms but cannot stop the
progression of neurodegeneration and disease development.
Thus, the main attempts in drug discovery are directed at
search for disease-modifying therapeutics. Also, due to the
complexity of neurodegenerative disorders, the focus is on
multitarget-directed ligands (MTDLs). MTDLs act on multi-
ple, carefully selected biological targets and therefore may
modify several pathological processes involved in the patho-
genesis of the disease.5
PF9601N, ASS234, and contilisant are indole- and N-
propargylamine-based multifunctional ligands developed in
Laboratory of Medicinal Chemistry in Madrid, Spain (Figure
1).6−9 They combine monoamine oxidase (MAO) inhibitory
potency with other biological activities relevant for the
treatment of PD and AD. Compound PF9601N is a dopamine
uptake inhibitor with neuroprotective effects demonstrated in
several cellular and in vivo models of PD.10,11 ASS234 inhibits
human cholinesterases (hAChE IC50 = 810 nM, hBuChE IC50
= 1820 nM), self-induced and AChE-induced Aβ aggregation
Received: July 29, 2020
Accepted: October 21, 2020
Published: November 3, 2020
Research Articlepubs.acs.org/chemneuro
© 2020 American Chemical Society
3793
https://dx.doi.org/10.1021/acschemneuro.0c00489
ACS Chem. Neurosci. 2020, 11, 3793−3801
This is an open access article published under a Creative Commons Attribution (CC-BY)
License, which permits unrestricted use, distribution and reproduction in any medium,




















































































and activates sigma-1 receptors (Ki hS1R = 3 nM).
7 It also
shows a protective effect against Aβ1−42-induced toxicity and
depletion of antioxidant enzymes in SH-SY5Y human neuro-
blastoma cells.12 Further ex vivo and in vivo studies showed that
ASS234 reduces the Aβ plaque burden and neuroinflammation
in the mouse cortex and displays significant improvements in
memory processes in a scopolamine-induced cognitive deficit
test, comparable with donepezil.7 Contilisant is the most
advanced preclinical candidate for the treatment of AD (Figure
1).8,9 Contilisant, like ASS234, also shows activity toward
cholinesterases (hAChE IC50 = 530 nM, hBuChE IC50 = 1690
nm) and is a sigma-1 receptor agonist (Ki hS1R = 65 nM), but
it also shows high activity toward the histamine H3 receptor
(H3R Ki = 11 nM). A multidirectional in vitro profile of
contilisant activity is reflected in its exceptional in cellulo and in
vivo profile. Contilisant protected SH-SY5Y human neuro-
blastoma cells against damages caused by ROS generators
(rotenone and oligomycin A), Aβ25−35 and hyperphosphor-
ylation of proteins caused by okadaic acid. Contilisant was
shown to restore cognitive impairment induced by Aβ
oligomers in Y-maze and radial maze assays and by
lipopolysaccharide in the novel object recognition test. To
sum up, PF9601N, ASS234, and contilisant are all interesting
compounds in terms of their biological properties and potential
utility in the treatment of neurodegenerative diseases such as
PD or AD.
Figure 1. Multifunctional MAO inhibitors as anti-Parkinson’s and anti-Alzheimer’s agents.
Figure 2. Major metabolic pathways predicted in ADMET Predictor and metabolites PF9610N-M, ASS234-M, contilisant-M, desmethylselegiline
(DS), and methamphetamine (MA) detected after incubation of PF9601N, ASS234, contilisant, and selegiline with HLMs.
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In the drug discovery process, equally important to the
biological activity of the compounds is their drug-likeness. It
arises from structural (e.g., molecular weight, polar surface
area, and hydrogen bond donor/acceptor count), physico-
chemical (e.g., solubility and chemical stability), or bio-
chemical (e.g., metabolic stability, selectivity, and off-target
activity) parameters that determine the absorption, distribu-
tion, metabolism, excretion, and toxicity (ADME-tox) profile
of each compound.13 These parameters should be considered
and optimized from the very beginning of the drug
development process. Herein, we focus on the selected
biochemical parameters (metabolic stability) and safety issues
and present a preliminary in vitro evaluation of metabolic
stability in human liver microsomes and cytochrome P450
isoenzymes inhibition and cytotoxicity on HEK-293, HepG2,
Huh7, and WTIIB cell lines of the known MTDLs, PF9601N,
ASS234, and contilisant (Figure 1), targeting processes
relevant to PD and AD.6−9
2. RESULTS AND DISCUSSION
2.1. Metabolic Stability. The metabolic stability of a
compound is an important factor that determines its
pharmacokinetics and its potential as a drug candidate.
Drugs are being metabolized in a variety of tissues including
lungs, kidneys, or intestinal walls, but the liver plays an
essential role in this process. Therefore, we have analyzed the
metabolic stability of PF9601N, ASS234, and contilisant in
vitro on human liver microsomes (HLMs). For comparison in
these studies, we have used selegiline, a marketed MAO
inhibitor which shares structural similarity with the tested
compounds. We have incubated the compounds with HLMs
for 2 h and analyzed the mixture with UPLC-MS, according to
the previously reported method (for details considering these
experiments, including UPLC-MS spectra, see the Supporting
Information).14 The common structural fragment in all the
compounds discussed herein, that is susceptible to metabolism,
in principle oxidative N-dealkylation, is N-(methyl)-
propargylamine. The experimental data showed that the
Figure 3. Influence of PF9601N, ASS234, contilisant and selegiline on (A) CYP3A4 activity, (B) CYP2D6 activity, and (C) CYP2C9 activity.
Statistical significance was evaluated by one-way ANOVA, followed by Bonferroni’s comparison test (*p < 0.05, **p < 0.01, ****p < 0.0001). KE,
ketoconazole; QD, quinidine; SE, sulfaphenazole.
ACS Chemical Neuroscience pubs.acs.org/chemneuro Research Article
https://dx.doi.org/10.1021/acschemneuro.0c00489
ACS Chem. Neurosci. 2020, 11, 3793−3801
3795
compounds are metabolized by N-demethylation (contilisant,
selegiline) and N-depropargylation (PF9601N, ASS234, selegi-
line) (Figure 2). This is indicated by molecular masses
decreased by 14 and by 38, corresponding the masses of
methyl and propargyl groups, respectively. Since there are two
spots where demethylation is possible in contilisant, we have
performed fragmentation analysis. It showed that the methyl
group in N-(methyl)propargylamine is removed. We were
happy to find that our experimental data are in line with the
metabolic pathways predicted by the ADMET Predictor tool.
For all the compounds the program predicted oxidative N-
dealkylation as one of two major metabolic pathways (Figure
2). According to the predictions, PF9601N is more susceptible
to para-hydroxylation of the benzyl ring, but this metabolite
did not occur in vitro. Considering the structural similarity of
the compounds, it was interesting to find out that while
PF9601N and contilisant are metabolically stable in vitro (95%
and 97% of the parent compounds respectively were detected),
selegiline is metabolized in about 54% and ASS234 was greatly
unstable (the compound was not detected). After a 2 h
incubation with ASS234, only its metabolite ASS234-M was
detected (Figure 2). Although it was quite surprising, these
results were confirmed by the predicted clearance of the
compounds, that was the lowest for contilisant (82.1 μL/min/
mg HLM protein), higher for PF9601N (140.1 μL/min/mg
HLM protein), and very high for ASS234 (358.8 μL/min/mg
HLM protein).
2.2. Influence on Cytochrome P450 (CYPs) Isoen-
zymes Activity. Cytochrome P450 enzymes (CYPs) are
responsible for the liver metabolic transformation of the
majority of drugs; therefore ,they are also sites of drug−drug
interactions. Inhibition or induction of CYPs by one drug may
lead to the accumulation, potential toxicity, or intensified
metabolism and therefore the lack of activity of the other one.
Additionally, the reactive terminal acetylene functionality in
MAO inhibitors not only determines their mechanism of
action but also is associated with mechanism-based inactivation
of CYPs.15 Consequently, assessing the impact of these
compounds on CYP activity is a crucial step in their
development. We tested the influence of PF9601N, ASS234,
contilisant, and selegiline on the activity of the most common
isoforms of Cytochrome P450, CYP3A4, CYP2D6, and
CYP2C9, and compared them with well-known inhibitors,
such as ketoconazole, quinidine, and sulfaphenazole, respec-
tively (Figure 3). CYP3A4 activity was decreased by PF9601N
at all the tested concentrations (0.1, 1, 10, and 25 μM), by
selegiline at 10 and 25 μM, and by ASS234 and contilisant only
at the highest concentration of 25 μM (Figure 3A). Regarding
the influence on CYP2D6 activity, the most potent inhibitor of
this enzyme was ASS234, which decreased enzyme activity at
1, 10, and 25 μM. Also, PF9601N and selegiline decreased
CYP2D6 activity at 10 and 25 μM, but contilisant, on the other
hand, seemed to increase the activity of the enzyme at the
same concentrations. Finally, we found that all the compounds
inhibited CYP2C9. It should be noted that the inhibitory
activities of the tested compounds against CYP3A4, CYP2D6,
and CYP2C9 were lower than the activities of ketoconazole,
quinidine, and sulfaphenazole used here as references. The
impact of contilisant and selegiline on CYP activity was
observed only at the highest tested concentrations (10 and 25
μM).
2.3. Cytotoxicity on Kidney HEK-293 and Liver
HepG2, Huh7, and WTIIB Cell Lines. Safety is among the
most important issues in the drug discovery process and, at the
same time, one of the major factors leading to drug failures.
High throughput in vitro cytotoxicity studies are well-
established methods that allow the early detection and
elimination of compounds with toxicity issues from further
development. In our studies, we determined the preliminary
safety of the compounds by measuring the viability of cells
exposed to these compounds. Due to some discrepancies16
that have been found when various methods used to measure
cell viability were compared, we used three different assays:
MTS, MTT that indirectly indicates the number of viable cells,
Figure 4. Cell viability measured in MTS assay on HEK-293 and HepG2 cell lines after incubation with PF9601N, ASS234, and contilisant for 72
h. (A) Concentration−response on HEK-293 cells. (B) Concentration−response on HepG2 cells. Statistical significance was evaluated by one-way
ANOVA, followed by Bonferroni’s comparison test (****p < 0.0001). DX, doxorubicin; CCCP, carbonyl cyanide 3-chlorophenyl hydrazine.
ASS234 precipitated at 100 μM during incubation.
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and crystal violet assay (CV), a direct method in which the
DNA mass of living cells is measured (Figure 4).17 We used
cell lines of different origin: human kidney HEK-293 and
human hepatic HepG2 cell lines that are commonly used in
drug metabolism and cytotoxicity studies. To extend the
cytotoxicity profile, we additionally used human hepatic Huh7
and murine WTIIB cell lines. ASS234 was previously tested in
HepG2 cells,18 but to further test its safety and to compare it
with two other compounds of interest, we included it in the
studies. First, all of the compounds were tested on HEK-293
and HepG2 cell lines in the MTS test. None of the compounds
decreased any cell line viability at the concentration of 1 μM.
Among the tested compounds, contilisant displayed the most
promising profile. It did not affect cell viability in the widest
range of concentrations, up to 10 μM on HEK-293 and up to
50 μM on HepG2 cells.
Additionally, ASS234 and contilisant were tested in a wider
range of concentrations (1−300 μM) in two assays, MTT and
CV, on two more cell lines, human hepatic Huh7 and murine
hepatic WTIIB. We obtained similar results independently of
the hepatic cell line and the viability assay used. From 30 μM
onward, the compounds began to elicit toxicity (Figure 5),
except for contilisant in WTIIB cells (Figure 5B and D), which
started at 100 μM in both assays. We observed that contilisant
was less toxic than ASS234 at the lowest toxic concentration
(30 μM, Figure 5A, and C). Furthermore, contilisant was less
toxic than ASS234 at the concentration of 100 μM when the
CV assay was used in WTIIB cells (Figure 5D). However, at
the highest concentration (300 μM), contilisant increased its
toxicity and became more toxic than ASS234 (Figure 5A−D)
in both cell lines. Nevertheless, this concentration is far higher
than the effective concentration of contilisant (0.3−3 μM)
used in neuroprotection experiments.8
2.4. In Silico Toxicity Studies. For more detailed
information in terms of safety of contilisant, we performed in
silico prediction of the potentially toxic effects of the
compound and its metabolites. We performed toxicity and
mutagenicity predictions with Derek Nexus that rely on the
comparison of the structural features of the tested compound
with one or more toxicophore patterns (structural alerts) in
Lhasa’s Knowledge Base.19
In terms of toxicity, from among 59 end points analyzed by
Derek Nexus for contilisant, no alerts were fired for 57 (see the
Supporting Information); α-2-μ-globulin nephropathy in
humans was considered impossible, and only hERG channel
inhibition in vitro in humans was considered plausible. The
blockage of this channel can lead to the lengthening of the
ventricular repolarization phase in the heart and is charac-
terized in the electrocardiogram as a prolongation of the QT
interval.20 As this is a common feature that makes molecules
fall out in the preclinical phases, a deeper investigation should
be performed for contilisant at this point.
The mutagenicity of contilisant was assessed by two
complementary QSAR methods: Derek Nexus (KB 2018
1.1) and Sarah Nexus (KB 2018 1.1). The compound did not
match any structural alerts or examples for bacterial in vitro
mutagenicity. Additionally, it did not contain any unclassified
or misclassified features and is consequently predicted to be
inactive in the bacterial in vitro mutagenicity test (Ames test).
Furthermore, predicted Phase I metabolites of contilisant were
evaluated in terms of toxicity and mutagenic potential (see the
Supporting Information for details). Results showed that, out
of 15, 7 metabolites were not associated with any probable/
plausible structural toxicity alerts by Derek, 7 were associated
with plausible hERG channel inhibition, and 1 was associated
with carcinogenic/teratogenic risk. In terms of carcinogenic
risk, both Derek (KB 2018 1.1) and Sarah (model 2.0)
predicted no structural alerts for contilisant and its 12
metabolites, which under ICH M7 guidelines is sufficient to
conclude that there is no mutagenic concern and no further
testing is recommended for them (Class 5). However, two
metabolites (M3, prop-2-yn-1-ol and M4, propiolic acid)
Figure 5. Cell viability measured in the MTT and crystal violet assays on Huh7 and WTIIB cell lines. Experiments were run in parallel using
contilisant, ASS234, and tacrine (300 μM). (A) Concentration−response on Huh7 cells measured by MTT assay after 24 h incubation with
compounds. (B) Concentration−response on WTIIB cells measured by MTT assay after 24 h incubation with compounds. (C) Concentration−
response on Huh7 cells measured by crystal violet assay after 24 h incubation with compounds. (D) Concentration−response on WTIIB cells
measured by crystal violet assay after 24 h incubation with compounds. Data correspond to the mean ± SEM of at least six different cell batches in
triplicate. ****p < 0.0001 and ***p < 0.001 with respect to ASS234 and basal nontreated groups. ####p < 0.0001, ##p < 0.01, and #p < 0.05
comparing contilisant with basal nontreated groups. $$$p < 0.001, $$p < 0.01, and $p < 0.05 comparing contilisant with ASS234 treated groups.
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obtained an uncertain result. Whereas Derek predicted a
confident negative prediction, Sarah gathered a positive or an
equivocal prediction. One metabolite fired a positive bacterial
mutagenicity result, after finding an exact match to be 100%
positive and overturning the negative result obtained by Derek.
Among these metabolites, only contilisant-M (Figure 3) was
the one detected in 3% after 2 h incubation of contilisant with
HLMs, as described above. It was associated with plausible
hERG channel inhibition and no other toxicity or mutagenicity
alerts.
In addition to the recommended studies, the concept of
Threshold of Toxicological Concern (TTC) has been
developed to define an acceptable intake for any unstudied
chemical that poses a negligible risk of carcinogenicity or other
toxic effects.21 The exposure to a metabolite identified as a
mutagen is not necessarily associated with an increased cancer
risk, additional analytical controls should be developed to
ensure that the mutagenic impurity is at or below the
acceptable cancer risk level.21 Despite the outcome detected
for M3, the existence of a potential impurity structural alert
alone is considered insufficient to assess carcinogenicity risk.
Considering TTC-based acceptable intake of mutagenic
impurity (1.5 μg person/day) can derive an acceptable limit
for control for long-term treatments. Indeed, the only
metabolite identified after HLMs incubation of contilisant
was contilisant-M, and only in 3%.
3. CONCLUSIONS
In this work, we have analyzed the metabolism, the inhibition
of cytochrome P450 isoenzymes activity, and the cytotoxicity
of PF9601N, ASS234, and contilisant, selected MTDLs
discovered in Laboratory of Medicinal Chemistry in Madrid
as potential therapeutic agents for neurodegenerative diseases,
such as AD and PD. These analyses would eventually provide
key pieces of information to support potential agent in
preclinical phases.
Regarding their metabolism, we have observed that the
compounds are metabolized by N-demethylation (contilisant)
and N-depropargylation (PF9601N, ASS234). Although they
have a similar pattern of metabolism in HLMs, which is due to
the structural similarities, they differ in terms of their stability
on HLMs and the predicted clearance. Very interestingly, while
ASS234 was greatly unstable, PF9601N and contilisant were
metabolically stable, results that were also confirmed in the
predicted clearance of the compounds, with the lowest for
contilisant, higher for PF9601N, and very high for ASS234.
This is a very important issue that guarantees a longer
sustained therapeutic effect at a much lower dose admin-
istration. It is worth mentioning that in these studies selegiline,
currently used in PD therapy, ranks between contilisant and
ASS234 which gives a definite advantage to contilisant.
Considering the inhibition of cytochrome P450 isoenzymes
activity, we tested the influence of PF9601N, ASS234, and
contilisant on the activity of CYP3A4, CYP2D6, and CYP2C9.
The inhibitory activities of the tested compounds against these
CYPs were lower than the activity of ketoconazole, quinidine,
and sulfaphenazole, the references used in this study.
Contilisant showed the most favorable profile when it comes
to interactions with CYPs, and its activity was similar to that of
selegiline.
Considering cytotoxicity, we have concluded that none of
the molecules decreased HEK-293 and HepG2 cell line
viability at the concentration of 1 μM and contilisant displayed
the most promising profile as it did not affect cell viability in
the widest range of concentrations also in Huh7 and WTIIB
cell lines. These concentrations were significantly higher than
the effective concentration of contilisant (0.3−3 μM) used in
neuroprotection cellular experiments.
Finally, according to Derek Nexus and Sarah Nexus
predictions, contilisant as well as its metabolites identified in
vitro do not fire mutagenicity alerts and it can be categorized in
ICH M7 as Class 5. In terms of toxicity, two positive or
equivocal results were obtained, which means that further
hazard assessment or control measures are needed (Class 2).
First, further metabolism studies should be developed to
confirm whether these metabolites really appear, and afterward,
the levels of these possible metabolites should be described.
To sum up, based on the precedent in vitro and in vivo
studies,8,9 coupled to the present ADME-tox studies, we have
identified the most attractive agent among our hit-agents
PF9601N, ASS234, and contilisant. Thus, MTDL contilisant is
metabolically stable, able to inhibit CYP3A4 only at 25 μM,
nontoxic, patented,22 and ready to be launched as a lead
compound in a preclinical program for AD therapy.
4. METHODS
ADME-tox parameters of PF9601N, ASS234, contilisant, and
selegiline were performed according to the previously described
assays and protocols.14,17,23 Statistical significances were analyzed by
GraphPad Prism 8.0 or GraphPad Prism 6.0 for Mac OS X using one-
way ANOVA followed by Bonferroni’s multiple comparison post test,
Newman−Keuls posthoc test, and Sidak’s posthoc test when
appropriate. Differences were considered to be statistically significant
when p ≤ 0.05.
4.1. Metabolic Stability. The metabolic pathway determination
in vitro was performed by 120 min incubation of PF9601N, ASS234,
contilisant, and selegiline with HLMs (Sigma-Aldrich, St. Louis, MO,
USA) in 10 mM Tris−HCl buffer (pH = 7.4) at 37 °C in the presence
of the NADPH Regeneration System (Promega, Madison, WI, USA).
Then, the UPLC/MS analyses were done by using a Waters
ACQUITY TQD system with the TQ Detector (Waters, Milford,
MA, USA). The in silico prediction of the most probable sites of
metabolism was done by ADMET Predictor, ver. 9.5.0.16, Lancaster,
CA, USA: Simulations Plus, Inc.; 2019, licensed for Jagiellonian
University Medical College.
4.2. Influence on Cytochrome P450 (CYPs) Isoenzymes
Activity. The potential drug−drug interactions were predicted using
CYP3A4, CYP2D6, and CYP2C9 P450-Glo assays purchased from
Promega (Madison, WI, USA) according to a manufacturer’s
protocol. PF9601N, ASS234, contilisant, and selegiline were tested
in triplicate at four concentrations (0.1, 1, 10, and 25 μM). As the
reference inhibitors, ketoconazole (KE), quinidine (QD), and
sulfaphenazole (SE) were used (Sigma-Aldrich, St. Louis, MO,
USA) for CYP3A4, CYP2D6, and CYP2C9, respectively.
4.3. Cytotoxicity on HEK-293 and HepG2 Cell Lines.
Cytotoxicity and hepatotoxicity were estimated using the human
embryonic kidney HEK-293 cell line (ATCC CRL-1573) and
hepatoma HepG2 (ATCC HB-8065) cell line. The CellTiter 96
Aqueous Non-Radioactive Cell Proliferation Assay (MTS) was
purchased from Promega (Madison, WI, USA) and performed
according to the manufacturer’s protocol. The viability of cells was
assessed after 72 h of incubation with PF9601N, ASS234, and
contilisant in quadruplicate at four concentrations (1, 10, 50, and 100
μM). The antiproliferative drug doxorubicin (DX) (1 μM) and
mitochondrial toxin carbonyl cyanide 3-chlorophenyl-hydrazone
(CCCP) (10 μM, only in hepatotoxicity assay) were used as positive
controls (purchased from Sigma-Aldrich, St. Louis, MO, USA).
4.4. Quantification of Cell Viability on Huh7 and WTIIB Cell
Lines. The human hepatoma cell line (Huh7) was purchased from
the American Type Culture Collection (ATCC, Manassas, VA, USA).
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The generation and characterization of the immortalized mouse
hepatocyte cell line WTIIB has been previously described.24 Cell
viability was measured by the quantitative colorimetric MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay as
previously described, and triarylmethane dye (violet) assay following
the protocol adapted from Feoktistova et al.25 After the incubation
period with the compounds, MTT reagent was added to each well at a
final concentration of 0.5 mg/mL. The plate was placed in a
humidified incubator at 37 °C with 5% CO2 and 95% air for 2 h.
Then, the precipitated formazan was dissolved with dimethyl sulfoxide
(DMSO) and the colorimetric determination of MTT was measured
in the spectrophotometer at 540 nm wavelength. Nontreated cells
were considered controls and were taken as 100% viability.
To perform the crystal violet assay, wells were washed twice in PBS
and cells were fixed with 100 μL of crystal violet (Sigma-Aldrich,
Madrid, Spain) solution at 0.2% prepared in ethanol. Plates were
incubated for 20 min at room temperature in a bench rocker. Next,
wells were washed four times with distilled water, and then the plate
was inverted gently to remove any remaining liquid. The plate was
dried at room temperature for at least 2 h and attached cells were
resuspended in SDS 1% for 30 min in a bench rocker. The optical
density was measured in the spectrophotometer at 540 nm
wavelength. Nontreated cells were considered controls and were
taken as 100% viability.
4.5. In Silico Prediction of Contilisant Toxicity. To assess
toxicity prediction, we used Derek Nexus ver. 6.0.1 (Knowledge Base
(KB) 2018 1.1, species: human), which is a knowledge-based expert
system by Lhasa Limited, where toxicity predictions consider the
presence of one or more toxicophore patterns in the query structure
and are the result of two processes: evaluating alerts and estimating
the likelihood of toxicity.19 The likelihood levels in Derek Nexus in
the highest to lowest order are certain, probable, plausible, equivocal,
doubted, improbable, and impossible.26
4.6. In Silico Prediction of Contilisant Metabolism. To predict
metabolism, we used Meteor Nexus ver. 3.1.0 (KB 2018 1.0.0). A
knowledge-based approach to rank metabolites based on known
metabolic reactions.19 To predict the first metabolic step of
contilisant, we analyze the Phase I biotransformation pathways,
combining two different methods.27 A qualitative [absolute reasoning
(AR)] and quantitative [site of metabolism (SOM) scoring]
assessment was applied, selecting the matching metabolites. The AR
evaluated the likelihood level for biotransformation to occur, and the
minimal likelihood level was settled in “plausible,” which means that
the weight of evidence supports the proposition.26 The SOM scoring
method uses experimental data for compounds that match the same
biotransformation, have similar molecular weights, and are chemically
similar around the site of metabolism to contilisant.
4.7. Mutagenic and Carcinogenic Risk Assessment. The
International Conference on Harmonisation (ICH) of technical
requirements for registration of pharmaceuticals for human use has
developed a guideline for the assessment and control of mutagenic
impurities to limit potential carcinogenic risk (ICH M7 Assessment
and Control of DNA Reactive (Mutagenic) Impurities In
Pharmaceuticals To Limit Potential Carcinogenic Risk). This
guideline purposes to provide a framework to identify mutagenic
alerts with computational toxicology assessment; it has to be
performed using two complementary QSAR methodologies. To
reach this objective, we have used an in silico prediction system from
Lhasa Ltd. (Leeds, UK), Derek Nexus ver. 3.2.0 (expert rule-based
methodology) and Sarah Nexus ver. 3.0.0 (statistical-based method-
ology) to obtain a classification (OECD.2007. Guidance document on
the validation of (quantitative) structure−activity relationships
[(Q)SAR] models. OECD Environment Health and Safety
Publications: Series on Testing and Assessment 69).
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for Drug I+D, School of Medicine, Autonomous University of
Madrid, 28029 Madrid, Spain
Victor Farre ́ Alíns − Health Research Institute, Clinical
Pharmacology Service, University Hospital La Princesa,
Autonomous University of Madrid, 28006 Madrid, Spain;
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